Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PETHEMA Foundation
Clinical Trial with a pharmaceutical speciality in new conditions to use.
Age
15–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients diagnosed with mature LLA-B cell (LLA-L3)
Patients diagnosed with Burkitt´s and Burkitt´s Like Lymphoma
Patients 15 years old or up
Written Informed Consent signed
You may not be if
Serious complications related with LAL3/LB or Secondary illness:
Serious complications, uncontrollable, for example, sepsis, pneumonia with hypoxia, shock, haemorrhage at diagnosis.
Renal failure unconditional for the Lymphoma/Leukemia
Heart failure or serious liver.
Pulmonary obstructive disease or serious restrictive that not allow to treat the patient with intensive chemotherapy.
Secondary Lymphoma after chemotherapy or previous radiotherapy or second malignant tumour.
Known hypersensitivity to any foreign protein.
Previous treatment with cytostatics of the LLA-B or Burkitt´s Lymphoma (exception: administration on short time of glucocorticoids ≤ 7 days, one administration of vincristine or cyclophosphamide, one cycle of CHOP, urgent administration of the another cytostatics).
With another malignant tumour in the last 5 year.
Women in fertile age must give positive in the pregnancy test or nursing mother.
Mental disability or emotional or psychiatric significant disorder were the patient can't understand nor cooperate with treatment.
Patients is enrolled in another clinical research study.
